Cancer In Depth: Myelodysplastic Syndrome (MDS)

MDS refers to a group of disorders that affect the bone marrow's ability to produce normal, healthy blood cells. This leads to problems with the immune system, oxygen delivery, and blood clotting.

Bone Marrow Sites in Adults
nucleus factsheet image
Copyright © Nucleus Medical Media, Inc.

Normal Blood Cells and the Development of MDS

All blood cells start as stem cells that are formed in the bone marrow. Stem cells can mature into a variety of different blood cell types that have specific functions in the body. These include:

  • Red blood cells—Carry oxygen from the lungs to the organs and cells of the body.
  • Platelets—Stop bleeding by clotting broken blood vessels in a chain of complex chemical reactions.
  • White blood cells—Main line of defense for the body's immune system.

New, healthy cells are developed in the bone marrow to replace old or damaged cells. This ensures there is a consistent number of blood cells in the body. With MDS, there is an excessive amount of stem cells that do not fully mature. The immature stem cells crowd the bone marrow making it difficult for new, healthy cells to develop. Overcrowding also pushes immature blood cells into the bloodstream too early. Immature blood cells are not fully formed enough to be functional. The lower levels of healthy cells lead to a weakened immune system, problems problems with oxygen delivery, or problems controlling bleeding depending on the type of blood cells that are affected.

The instruction for cell growth and cell death exists in the DNA of each cell. Primary MDS is the result of damage to DNA. The damage may be the result of genetics, environmental factors like radiation exposure, changes related to age, or a combination of these factors. Secondary MDS is associated with a history of cancer treatment. Chemo- and radiation therapy can damage the bone marrow and how it functions.

Cancer Cell Growth
IMAGE
Copyright © Nucleus Medical Media, Inc.

Types of MDS

The World Health Organization (WHO) identifies several types of MDS. Each type has certain characteristics based on how bone marrow or blood cells look under a microscope. They include:

  • Refractory cytopenia with multilineage dysplasia (RCMD)—This is the most common type of MDS, which is found in nearly half of all cases. RCMD affects at least 2 types of blood cells. In some people, RCMD progresses into acute myeloid leukemia (AML), a disease in which there is an overproduction of a type of white blood cell.
  • Refractory anemia with ringed sideroblasts (RARS)—Characterized by low numbers of red blood cells, and normal numbers of white blood cells and platelets.
  • Refractory cytopenia with unilineage dysplasia (RCUD)—Characterized by low numbers of one type of blood cell, and normal numbers of the other two. This type of MDS generally has the best outcome and rarely progresses to AML.
  • Refractory anemia with excess blasts-1 (RAEB-1)—One or more blood cell types are abnormally low. Some immature blood cells may be present in the bloodstream
  • Refractory anemia with excess blasts-2 (RAEB-2)—Similar to RAEB-1, except the bone marrow is crowded with more immature blood cells.
  • Myelodysplastic syndrome, unclassified (MDS-U)—The characteristics of blood and bone marrow cells do not fit into any other classification. This type is not common.
  • Myelodysplastic syndrome associated with isolated del (5q) abnormality—A specific chromosome in the bone marrow cells is missing. Red blood cell counts are low, but white cell counts are normal. There may be an increased number of platelets.

Revisions

Please note, not all procedures included in this resource library are available at Henry Ford Allegiance Health or performed by Henry Ford Allegiance Health physicians.

All EBSCO Publishing proprietary, consumer health and medical information found on this site is accredited by URAC. URAC's Health Web Site Accreditation Program requires compliance with 53 rigorous standards of quality and accountability, verified by independent audits. To send comments or feedback to our Editorial Team regarding the content please email us at HLEditorialTeam@ebscohost.com.

This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.

Editorial Policy | Privacy Policy | Terms and Conditions | Support
Copyright © 2008 EBSCO Publishing. All rights reserved.

Your generous gifts make it possible to treat our patients with leading-edge technology and nationally recognized care.